This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Emergent's (EBS) Chikungunya Vaccine Positive in Phase II Study
by Zacks Equity Research
Emergent (EBS) posts interim data from the phase II study on its chikungunya vaccine, CHIKV-VLP. The candidate generates positive immune response against the chikungunya virus.
Kamada to Begin Phase III Study for Inhaled AAT Product in 2H
by Zacks Equity Research
Kamada (KMDA) wins the FDA acceptance for the path forward regarding its inhaled Alpha-1-Antitrypsin product, currently under development for treating Alpha-1 Antitrypsin Deficiency.
Axsome's AXS-05 Meets Goal in Phase II Study, Shares Up
by Zacks Equity Research
Axsome's (AXSM) mid-stage candidate, AXS-05, achieves the primary endpoint in a phase II study as a smoking cessation treatment. Shares rise.
Fibrocell Out-licenses Skin Disease Gene Therapy, Stock Rises
by Zacks Equity Research
Fibrocell (FCSC) collaborates with Castle Creek to develop/commercialize its gene therapy candidate, FCX-007, for the rare skin disease of recessive dystrophic epidermolysis bullosa. Stock jumps.
Mallinckrodt (MNK) Completes Enrollment in Skin Tissue Study
by Zacks Equity Research
Mallinckrodt (MNK) ends enrollment in the phase III study on StrataGraft, a regenerative skin tissue used in patients with thermal burns.
PDL BioPharma (PDLI) Up 9.2% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
PDL BioPharma (PDLI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Acorda to Gain From Inbrija Sales and Neurological Pipeline
by Zacks Equity Research
Acorda (ACOR) aims to boost sales with the launch of its newly FDA-approved Parkinson's disease drug, Inbrija. The company's pipeline looks promising as well.
PDL BioPharma (PDLI) is a Great Momentum Stock: Should You Buy?
by Zacks Equity Research
Does PDL BioPharma (PDLI) have what it takes to be a top stock pick for momentum investors? Let's find out.
Inovio Earns 3rd Milestone Fee From AstraZeneca for MEDI0457
by Zacks Equity Research
Inovio (INO) receives the third milestone payment from AstraZeneca post the initiation of dosing in a phase II combo study of the latter's MEDI0457 for HPV related anal, penile and vulvar cancers.
Puma Biotech Adds Two Cohorts to Nerlynx Label Expansion Study
by Zacks Equity Research
Puma Biotech (PBYI) increases cohorts in the phase II SUMMIT basket study on Nerlynx for cancer patients suffering tumors with activating EGFR or HER2 mutations.
Puma Biotech Out-Licenses Nerlynx Rights in Europe, Stock Down
by Zacks Equity Research
Puma Biotech (PBYI) out-licenses development and marketing rights to its breast cancer drug Nerlynx to Pierre Fabre in Europe and across some African countries. Shares fall.
Blueprint Medicines Expediates Filings for Key Candidates
by Zacks Equity Research
Blueprint Medicines (BPMC) revs up the regulatory filling plans for its cancer candidates, avapritinib and BLU-667.
Agios (AGIO) Surges More Than 40% Year to Date: Here's Why
by Zacks Equity Research
Agios' (AGIO) first wholly owned precision medicine, Tibsovo, has been picking up the sales pace since its FDA approval last year with strong sequential growth delivered in Q4.
Agios Gains Breakthrough Therapy Status for Tibsovo Combo
by Zacks Equity Research
Agios (AGIO) receives a Breakthrough Therapy designation for Tibsovo combo to treat the newly diagnosed acute myeloid leukemia in adult patients with an IDH1 mutation.
PDL BioPharma (PDLI) Q4 Earnings Top Mark, Revenues Fall Y/Y
by Zacks Equity Research
PDL BioPharma's (PDLI) earnings exceed estimates in Q4. Lower royalties as well as weak product sales induce a downfall in year-over-year revenues.
PDL BioPharma (PDLI) Up 2.4% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
PDL BioPharma (PDLI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
PDL BioPharma (PDLI) Q3 Earnings Top, Revenues Rise, Stock Up
by Zacks Equity Research
PDL BioPharma's (PDLI) earnings trump estimates in Q3. Higher royalties and product sales aid a significant surge in year-over-year revenues.
Is PDL BioPharma (PDLI) a Great Stock for Value Investors?
by Zacks Equity Research
Is PDL BioPharma (PDLI) a great pick from the value investor's perspective right now? Read on to know more.
Why Is PDL BioPharma (PDLI) Up 2.5% Since Last Earnings Report?
by Zacks Equity Research
PDL BioPharma (PDLI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
PDL BioPharma (PDLI) Q2 Earnings Top, Revenues Slump Y/Y
by Zacks Equity Research
PDL BioPharma's (PDLI) earnings trump estimates in Q2. Lower royalties and license fees cause a significant decline in year-over-year revenues.
Is PDL BioPharma (PDLI) a Great Stock for Value Investors?
by Zacks Equity Research
Let's see if PDL BioPharma, Inc. (PDLI)stock is a good choice for value-oriented investors right now from multiple angles.
Arena's (ARNA) Etrasimod Meets Phase II Colitis Study Goal
by Zacks Equity Research
Arena's (ARNA) ulcerative colitis candidate, etrasimod leads to clinical remission in 33% of the patients.
Is PDL BioPharma (PDLI) a Great Stock for Value Investors Right Now?
by Zacks Equity Research
PDL BioPharma (PDLI) is an inspired choice for value investors, as it is hard to beat its incredible lineup of statistics on this front.
PDL BioPharma (PDLI) Q4 Earnings Beat, Revenues Rise Y/Y
by Zacks Equity Research
PDL BioPharma's (PDLI) earnings top estimates in Q4. Revenues also grow year over owing to rise in royalty rights.
PDL BioPharma, Inc. (PDLI) Jumps: Stock Rises 8.2%
by Zacks Equity Research
PDL BioPharma, Inc, (PDLI) was a big mover last session, as the company saw its shares more than 8% on the day amid huge volumes.